Navigation Links
Phase 3 Topical Drug for Raynaud's Disease Available for Licensing/Acquisition at the J.P. Morgan Conference
Date:12/13/2012

BOTHELL, Wash., Dec. 13, 2012 /PRNewswire-iReach/ -- MediQuest Therapeutics Inc., a specialty pharmaceutical company focused on inflammatory skin diseases and conditions, today announced that they will be conducting partnering/M&A meetings at the J.P. Morgan 31st Annual Healthcare Conference between January 7th and 10th in San Francisco, regarding its Phase 3 topical formulation, VASCANA, designed to treat Raynaud's Disease, an unmet medical need. MediQuest is also selling/licensing the remainder of its topical assets including a skin lightener, ready for commercialization.  Its topical/non-systemic Onychomycosis drug was out-licensed in August 2012.

(Photo: http://photos.prnewswire.com/prnh/20121213/CG29278)

MediQuest's VASCANA has a Special Protocol Assessment granted by the Federal Food & Drug Administration for a single Phase 3 study involving approximately 150 patients that suffer from moderate to severe symptoms of Raynaud's Syndrome.  VASCANA has a strong safety profile and an extensive intellectual property portfolio with issued patents that run to 2026.   The peak sales in the United States is estimated at about $250 million, as well as similar markets in EU and Asia, with low cost of goods, supported by 2-years of stability data.

Any company interested in learning more about VASCANA can arrange to meet with MediQuest at the J.P. Morgan conference through the below contact information.  

About Raynaud's Disease
An estimated 9-11 million people in the United States suffer from Raynaud's Disease, 2.1 million of which have been diagnosed and are seeking medical treatment. Raynaud's patients can experience severe pain associated with chronic vasospasm episodes in their hands, feet and other extremities.

About MediQuest Therapeutics, Inc.
MediQuest Therapeutics is a specialty pharmaceutical company using its proprie
'/>"/>

SOURCE MediQuest Therapeutics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Lilly Discontinues One of Three Phase 3 Rheumatoid Arthritis Registration Studies for Tabalumab
2. AstraZeneca Announces Top-Line Results of OSKIRA-4 Phase IIb Study of Fostamatinib as a Monotherapy for Rheumatoid Arthritis
3. Insero Health Completes Phase I Trial of Novel Therapy in Patients With Drug Resistant Epilepsy
4. Unigenes Phase 2 Study of Oral PTH for the Treatment of Osteoporosis in Postmenopausal Women Featured in Bone
5. Follow-up Results of Phase 2 Study of Investigational Agent, Ibrutinib, in Relapsed/Refractory Mantle Cell Lymphoma Presented at American Society of Hematology Annual Meeting
6. Follow-up Results of Phase 2 Study of Investigational Agent, Ibrutinib, Suggest High and Durable Responses in Relapsed/Refractory Mantle Cell Lymphoma
7. uniQure Initiates Phase I in Acute Intermittent Porphyria
8. Ambit and Astellas Announce Presentation of Results from Phase 2 ACE Study of Quizartinib in Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML) at the 54th Annual Meeting of the American Society of Hematology
9. Boehringer Ingelheim Presents New Phase II Data for Volasertib in Adult Patients with AML
10. Spinifex Announces Start of Phase 2 Proof-of-Concept Trial of EMA401 in Chemotherapy-Induced Peripheral Neuropathy
11. Phase II Trial of Sanofi JAK2 Inhibitor in Myelofibrosis Met Primary Endpoint
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/4/2015)... 2015 Research and Markets ( ... Report on China,s Sodium Ibandronate Market, 2010-2019" report to ... clinic under the trade name of Bondronat in ... 1996, sodium ibandronate was approved by the FDA to come ... the trade name of Boniva. However, since drug makers later ...
(Date:9/4/2015)... , September 4, 2015 ... today announces that Hutchison MediPharma Limited ("HMP"), its ... in the second proof-of-concept ("POC") trial of fruquintinib ... cancer ("NSCLC") in China . ... succeeded in meeting the primary efficacy endpoint of ...
(Date:9/3/2015)... , Sept. 3, 2015 ... New Guide to that Market, its R&D and Sales Potentials ... assess the future of cancer-treating medicines? Visiongain,s new report gives ... stay ahead. There you discover financial data, R&D trends, opportunities, ... In our analysis you see forecasted sales to 2025 ...
Breaking Medicine Technology:Investigation Report on China's Sodium Ibandronate Market 2010-2019 2Second Proof-of-concept Trial of Fruquintinib Achieves its Primary Endpoint 2Second Proof-of-concept Trial of Fruquintinib Achieves its Primary Endpoint 3World Cancer-Treating Drugs Industry and Market: Companies, Therapies, R&D and Forecasts 2015-2025 2World Cancer-Treating Drugs Industry and Market: Companies, Therapies, R&D and Forecasts 2015-2025 3World Cancer-Treating Drugs Industry and Market: Companies, Therapies, R&D and Forecasts 2015-2025 4World Cancer-Treating Drugs Industry and Market: Companies, Therapies, R&D and Forecasts 2015-2025 5World Cancer-Treating Drugs Industry and Market: Companies, Therapies, R&D and Forecasts 2015-2025 6World Cancer-Treating Drugs Industry and Market: Companies, Therapies, R&D and Forecasts 2015-2025 7
... Reportlinker.com announces that a new market research ... Chinese Markets for Bladder Cancer Treatment Drugs ... , China,s demand ... a fast pace in the past decade. In ...
... , REDMOND, Wash., Nov. 3 Medical software company ... availability of FiatLux Visualize(TM) Free, advanced 2D/3D visualization software ... is available for any healthcare professional via download from ... , "There is tremendous unrealized potential in medical ...
Cached Medicine Technology:Reportlinker Adds Chinese Markets for Bladder Cancer Treatment Drugs 2Reportlinker Adds Chinese Markets for Bladder Cancer Treatment Drugs 3Reportlinker Adds Chinese Markets for Bladder Cancer Treatment Drugs 4Reportlinker Adds Chinese Markets for Bladder Cancer Treatment Drugs 5Free 2D/3D Advanced Visualization Software for CT and MRI Now Available From FiatLux Imaging 2
(Date:9/4/2015)... ... September 04, 2015 , ... ... is now available at CitiDent. CEREC is a newer method for creating restorations ... time for patients by eliminating the need for multiple appointments, CEREC produces restorations ...
(Date:9/4/2015)... ... September 04, 2015 , ... Many consumers are looking for a quick and convenient way to ... The patent-pending K Med Cups provide a quick and simple way to brew a hot ... flu or cough. As a result, they enhance comfort and health. The invention features a ...
(Date:9/4/2015)... (PRWEB) , ... September 04, 2015 , ... ... on: the microbiome taking place in Hollywood, Florida October 9-10, 2015 at the ... Speakers at the 2015 symposium are doctors and researchers at the top of ...
(Date:9/4/2015)... , ... September 04, 2015 , ... Lalonde Gordon ran ... and followed up with victory in the men’s 400 meters final, with an impressive ... and Field Championships in San Jose, Costa Rica in August 2015. The 44.64 time ...
(Date:9/4/2015)... Texas (PRWEB) , ... September 04, 2015 , ... Yisrayl Hawkins, Pastor and Overseer at ... he says are prophetic details involving the Pope’s upcoming trip to the United States. , ... details what his role with the Vatican and society is. Yisrayl also provides the meaning ...
Breaking Medicine News(10 mins):Health News:San Francisco Dentist, Dr. Ben Amini, is Now Offering CEREC Technology at CitiDent 2Health News:Redesigned Packaging for Powdered Medicinal Mix Invented by InventHelp® Client (CBA-2637) 2Health News:Integrative Healthcare Symposium Focus On: The Microbiome Conference Program Announced 2Health News:Lalonde Gordon’s Recipe Brings Home the Gold 2Health News:Lalonde Gordon’s Recipe Brings Home the Gold 3Health News:Yisrayl Hawkins Writes Open Letter to Pope Francis In Light of Approaching U.S. Visit 2
... months of life, but not fetal growth, is associated with ... to a new study from The Generation R Study Group ... that low birth weight is associated with an increased risk ... fetal and infant growth patterns on this risk had not ...
... , THURSDAY, Jan. 19 (HealthDay News) -- Many ... tract, a problem that can cause serious health problems and ... said their findings show that more needs to be done ... in the esophagus, stomach or first part of the intestine ...
... growing need for family-friendly workplace policies, a new study ... with support from the Rockefeller Foundation, concludes that providing ... outcomes for working families, businesses and the public. ... Work at Rutgers, the State University of New Jersey, ...
... Reporter , THURSDAY, Jan. 19 (HealthDay News) -- The number ... for HIV infection has declined significantly, federal health officials reported ... sexual or drug-related behavior dropped from 13 percent of men ... and 8 percent, respectively, in 2010, according to the U.S. ...
... of autism is now well established, a growing body of ... in this serious developmental disorder affecting nearly one in 100 ... that low birth weight is an important environmental factor contributing ... "Our study of discordant twins -- twin pairs in which ...
... cause of blindness in the Western World. A report from ... today shows the number of new cases of blindness and ... last ten years. The study just published in ... 11,848 new cases of legal blindness. The rate of blindness ...
Cached Medicine News:Health News:Accelerated infant growth increases risk of future asthma symptoms in children 2Health News:Kidney Failure Patients Prone to GI Tract Bleeding 2Health News:Rutgers study finds paid family leave leads to positive economic outcomes 2Health News:Rutgers study finds paid family leave leads to positive economic outcomes 3Health News:More Americans Practicing Safe Sex, CDC Reports 2Health News:More Americans Practicing Safe Sex, CDC Reports 3Health News:Another clue in the mystery of autism 2Health News:Report shows risk of blindness halved over last decade 2
... 48-capillary 3730 DNA Analyzer, upgradeable to 96 ... DNA analysis. , Higher optical sensitivity ... higher-quality data at a lower cost. , ... , Optimized polymers increase your productivity without ...
... this unique offer, you can ... application. Pipetman P2 and P10 ... reagents, and P100 is perfect ... Filter Tips, which are especially ...
... is an immunochromatography based one step ... qualitative determination of Methamphetamine in human ... 1000 ng/mL. This assay has not ... care,location and is for use by ...
... The RapidAMP test is an ... test. It is,designed for qualitative determination ... above,a cut-off level of 1000 ng/mL. ... in the point of care,location and ...
Medicine Products: